CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 18 enrolled
Drug / intervention
Pembrolizumab +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02337686
NCT02337686Phase 2Active
CompareCT.gov

Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma

M.D. Anderson Cancer Center·interventional·Posted Jan 14, 2015·Updated Aug 15, 2025

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Pembrolizumab, and 2 other interventions for Recurrent Glioblastoma and Recurrent Gliosarcoma. Active but no longer recruiting, targeting 18 participants across 1 site.

Detailed Summary

This phase II trial studies the effects of pembrolizumab on the body, or pharmacodynamics, in patients with glioblastoma that has come back. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Glioblastoma, Recurrent Gliosarcoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2Active
2015201620172018201920202021202220232024202520262027
First PostedJan 14, 2015
Enrollment StartApr 28, 2015
Primary CompletionMay 24, 2017
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.5 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Pembrolizumabbiological

Given IV

Pharmacological Studyother

Correlative studies

Therapeutic Conventional Surgeryprocedure

Undergo surgery